Phase III allergy studies present unique challenges for sponsors, particularly when recruitment depends on a fixed seasonal window, sites must be activated rapidly across multiple countries, and any delay can push enrollment into the next season.
When timelines are non-negotiable, sponsors need a delivery model that combines accelerated start-up, proactive site management, cross-functional coordination, and strong operational oversight. In this case study, Ergomed Clinical Research delivered a multi-country HDM allergy study across 6 European countries and 112 selected sites, completing recruitment within a single allergy season while exceeding the original enrollment target and maintaining quality and compliance.
Read our case study to explore more about:
- How to accelerate start-up and site activation in a complex, time-critical Phase III study
- How proactive site management and centralized RBQM can help stabilize recruitment performance
- How cross-functional execution supports continuity across supply, equipment, monitoring, and data readiness
- How Ergomed protected timelines, exceeded recruitment targets, and maintained data quality within a single seasonal window